- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00100672
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
Phase I Study of an Easy-to-Use Intravenous Formulation of Liposome Entrapped C-raf Antisense Oligonucleotide (LErafAON-ETU) Administered on a Weekly Schedule in Patients With Advanced Cancer
The primary purpose of this study is to identify a dose of Liposome Entrapped c-raf Antisense Oligonucleotide Easy-to-Use (LErafAON-ETU) which maximizes potential benefits of the compound to patients with advanced cancer, without compromising their safety. This study will also assess the processing of LErafAON-ETU by the body over time. Patients will receive an intravenous infusion of LErafAON-ETU each week. Multiple blood samples will be taken for pharmacokinetic analysis during the first treatment; two samples will be taken during both the second and third treatments. Patients will be eligible to continue treatment until the occurrence of unacceptable toxicity or disease progression.
In LErafAON-ETU, antisense oligonucleotides specific to c-raf, are associated with liposomes, which are microscopic membrane-like structures created from lipids (fats). Raf-1 is a protein which plays a critical role in many aspects of cellular activation and growth. Therefore, it is thought to be an important factor that may support tumor development. LErafAON-ETU potentially limits the ability of a cell to produce the Raf-1 protein.
Study Overview
Detailed Description
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- premiere Oncology-Arizona
-
-
California
-
Santa Monica, California, United States, 90404
- Premiere Oncology-Santa Monica
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be included in this study, patients must meet the following criteria:
- Be ≥18 years of age.
- Have advanced (local and/or metastatic) histologically documented cancer not considered responsive to available conventional modalities or treatment (i.e., no life prolonging therapy or therapy with a greater potential for patient benefit is available).
- Have an ECOG Performance status of 0-1.
- Have a life expectancy of >12 weeks.
- Have recovered from acute toxicities of prior treatment: *No treatment with radiotherapy or with cytotoxic or biologic agents within 3 weeks prior to study entry. At least 2 weeks must have elapsed since any prior surgery or granulocyte-stimulating growth factor therapy. Chronic treatment with non-investigational gonadotropin-releasing hormone agonists or other hormonal or supportive care is permitted. Concurrent bisphosphonate treatment is permitted if initiated ≥90 days prior to study entry. *Chronic Grade 1 toxicities due to prior treatment or other causes are permitted.
Be in adequate condition as evidenced by the following clinical laboratory values:
- Absolute neutrophil count (ANC) ≥1,500/mm³,
- Hemoglobin ≥9.0 g/dL,
- Platelets ≥125,000/mm³,
- PT, aPTT, creatinine, calcium, and total bilirubin ≤the institutional upper limit of normal (ULN),
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN,
- Alkaline phosphatase ≤2.5 x ULN
- Patients (male and female) must be willing to practice an effective method of birth control during the study.
- Patient must understand the investigational nature of this study and sign an Institutional Review Board (IRB) approved informed consent form prior to the performance of any study specific procedure.
Exclusion Criteria:
Patients are excluded from this study for the following:
- Active uncontrolled bleeding or bleeding diathesis (e.g., active peptic ulcer disease).
- Any active infection requiring parenteral or oral antibiotic treatment.
- Known infection with human immunodeficiency virus or hepatitis virus.
- Active heart disease including myocardial infarction within the previous 6 months, symptomatic coronary artery disease, arrhythmias currently requiring medication, or congestive heart failure.
- Known or suspected active central nervous system metastasis (patients stable 8 weeks after completion of treatment for central nervous system metastasis are eligible).
- Requiring immediate palliative treatment of any kind, including surgery and/or radiotherapy
- Concurrent anti-tumor therapy (except for chronic hormonal anti-tumor therapy).
- Treatment with any investigational drug within the 30-day period prior to enrollment in the study.
- Known hypersensitivity to any of the components of LErafAON-ETU.
- Prior treatment with LErafAON (previous sonicated formulation).
- Female patients who are pregnant or breast-feeding.
- Unwilling or unable to follow protocol requirements.
- Any consideration which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of LErafAON-ETU.
|
Secondary Outcome Measures
Outcome Measure |
---|
To determine the pharmacokinetics of raf antisense oligonucleotide after intravenous administration of LErafAON-ETU
|
To determine any anti-tumor effects of LErafAON-ETU.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LErafAON-ETU-104-R02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedUterine Neoplasms | Prostatic Neoplasms | Cervix Neoplasms | Bladder NeoplasmsCanada
-
N.N. Petrov National Medical Research Center of...Active, not recruitingColonic Neoplasms MalignantRussian Federation
-
Peking University First HospitalShengli Oilfield Hospital; The Second Affiliated Hospital of Baotou Medical...Enrolling by invitationRectal Neoplasms MalignantChina
-
Cancer Institute and Hospital, Chinese Academy...CompletedRectal Neoplasms MalignantChina
-
Seattle Children's HospitalSuspendedNeoplasms, Benign | Neoplasms, MalignantUnited States
-
Iuliu Hatieganu University of Medicine and PharmacyInstitutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian...CompletedRetroperitoneal NeoplasmsRomania
-
Pennington Biomedical Research CenterNational Cancer Institute (NCI)RecruitingRectal Neoplasms | Colonic NeoplasmsUnited States
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruitingRadiotherapy | Rectal Neoplasms MalignantChina
Clinical Trials on LErafAON-ETU
-
INSYS Therapeutics IncGeorgetown UniversityCompletedNeoplasmsUnited States
-
INSYS Therapeutics IncGeorgetown UniversityCompleted
-
INSYS Therapeutics IncCompleted
-
INSYS Therapeutics IncCompletedNeoplasmUnited States, Germany, Netherlands